Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Grace Ma

Plastic and Reconstructive Surgery Atlanta, GA Medical Doctor

NPI 1992707335 CMS profile 363125

3131 Maple Dr Ne Ste 100, Atlanta, GA 30305

Open in the dashboard

General payments

$16,622

476 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Grace Ma of Atlanta, GA is reported in the CMS Open Payments database as having received $16,622 across 476 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,010 62
2024 General $3,475 90
2023 General $3,539 77
2022 General $1,460 65
2021 General $2,705 76
2020 General $2,002 40
2019 General $1,432 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Grace Ma
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Grace Ma were reported at $2,010. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Grace Ma Plastic and Reconstructive Surgery median Middle half National median
2019 $1,432 $335 $121–$1,264 $163
2020 $2,002 $162 $57–$417 $114
2021 $2,705 $245 $89–$735 $132
2022 $1,460 $325 $120–$932 $149
2023 $3,539 $343 $129–$999 $160
2024 $3,475 $390 $141–$1,085 $164
2025 $2,010 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mentor Worldwide LLC $5,518 178 payments
  2. AbbVie, Inc. $2,603 116 payments
  3. Allergan Inc. $2,148 105 payments
  4. AxoGen $1,651 12 payments
  5. RTI Surgical, Inc $1,337 2 payments
  6. Musculoskeletal Transplant Foundation Inc. $1,090 10 payments
  7. Bard Peripheral Vascular, Inc. $839 11 payments
  8. Merz North America, Inc. $330 5 payments
  9. Integra LifeSciences Corporation $209 9 payments
  10. Davol Inc. $204 5 payments
  11. Other $693 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,956 474 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,200 1 payment
  3. Travel and Lodging $465 1 payment
Products named General payments · program years 2019–2025
  1. MENTOR MemoryGel Resterilizable Gel Sizer $4,111 127 payments
  2. ALLODERM $1,795 78 payments
  3. Avance Nerve Graft $1,401 7 payments
  4. CORTIVA ALLOGRAFT DERMIS $1,337 2 payments
  5. AXOGUARD NERVE PROTECTOR $1,189 6 payments
  6. AxoGuard Nerve Connector $1,189 6 payments
  7. AXOGUARD NERVE CAP $1,174 5 payments
  8. Axoguard HA+ Nerve Protector $1,174 5 payments
  9. NATRELLE $1,007 45 payments
  10. NATRELLE SALINE-FILLED BREAST IMPLANTS $890 41 payments
  11. Other $4,988 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

50

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$429

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

26%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Monohydrate Generic 14 $201
Ondansetron Odt Ondansetron Brand 13 $125
Cefadroxil Generic 11 $74
Tramadol Hcl Generic 12 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$20,744

Medicare's payments for the services billed

Medicare patients

51

Average age 72

Services billed

114

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 63%
Arthritis 31%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

476 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record